Intravenous Solutions Market Research, 2031
The global intravenous solutions market size was valued at $11,857.7 million in 2021, and is projected to reach $26,558.4 million by 2031, registering a CAGR of 8.3% from 2022 to 2031. The intravenous fluid regulation is the control of the amount of fluid received intravenously that is through bloodstream. The fluid is given from a bag connected to an intravenous line. This is a thin tube, often called an IV, that’s inserted into one of the veins. Fluids are administered this way for various reasons that may include proper control of the amount given. Without control, the rate of fluid administration relies on gravity alone. This can result in receiving either too much or too little fluid. This therapy may be used in rehydration after becoming dehydrated from illness or excessive activity. Fluids for such treatments consist of water with electrolytes, sugar and nutrients added in concentrations that depend on patient body need. The four main types of IV fluids include the normal saline, half normal saline, lactated ringers and dextrose. These fluids may be of types like crystalloids or colloids. Moreover, a crystalloid or colloid solution can also be isotonic, hypotonic, or hypertonic, and that directly affects what that solution is used for.
Growth of the intravenous solutions market size is driven by increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population.
In addition, increase in prevalence of cancer and rise in natality rate are projected to supplement the growth in intravenous solutions market share. On the other hand, lack of experienced healthcare professionals and complications of intravenous administration therapy are expected to hinder the growth of the market. Conversely, the high growth opportunities in emerging markets offer intravenous solutions market opportunity.
Impact of COVID-19 Pandemic on Intravenous Solutions Market
The COVID-19 pandemic affected the intravenous solutions industry in a fairly positive way. According to the guidelines by American Society for Parenteral and Enteral Nutrition (ASPEN), in 2020, the early parenteral nutrition should be initiated as soon as possible in the high-risk patient for whom early gastric enteral nutrition is not feasible. It will bring down the concerns for ischemic bowel and also reduce the droplet aerosol transmission to healthcare providers by avoiding procedures involved in the initial placement and maintenance of an enteral access device. Moreover, the delivery of nutritional therapy to the patient with COVID-19 disease should follow the basic principles of critical care nutrition as recommended by European and North American societal guidelines in 2020.
Overall, the COVID-19 pandemic had a fairly positive impact on the intravenous solutions industry owing to the increased research and developments activities about the role of intravenous solutions in the COVID-19 pandemic. Moreover, increase in prevalence of some metabolic diseases also boosted the intravenous solutions market growth amidst the pandemic situation.
Intravenous Solutions Market Segmentation
The intravenous solutions market is segmented into Type, Composition and End Users. By type, the market is classified into partial parenteral nutrition and total parenteral nutrition. Furthermore, the partial parenteral nutrition is sub-classified as pediatric and adult. Also, the total parenteral nutrition is sub-classified as pediatric and adult. By composition, the market is classified into carbohydrates, vitamins and minerals, single dose amino acids, parenteral lipid emulsion and others. By end user, the market is classified into hospitals and clinics, ambulatory surgery centers, home care settings. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).
Market By Type Segment Review
By type, the total parenteral nutrition segment is anticipated to grow with the largest share during the forecast period. This is attributed to the increase in the use of total parenteral nutrition. On the other side, the partial parenteral nutrition segment is projected to exhibit the fastest market growth during the forecast period owing to new product launches and increase in the demand of its products.
Market By Composition Segment Review
By composition, the single dose amino acids segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period due to increase in number of patients of cancer. In addition, adoption of unhealthy lifestyle, increase in geriatric population, and surge in governmental initiatives contributed toward the growth of the market. On the other side, the vitamins and minerals segment is projected to exhibit the fastest market growth during the forecast period, owing to increase in geriatric population, surge in technological advancements, and rise in efficacy and advantages of vitamins and mineral preparations.
Market By End User Segment Review
By end user, hospitals and clinics segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period due to increase in number of hospitals and clinics and increase in the prevalence of metabolic problems. On the other side the home care settings segment is projected to exhibit the fastest growth during the intravenous solutions market forecast period, owing to increase in geriatric population.
Market By Region Review
Europe accounted for the largest intravenous solutions market share in 2021, and is anticipated to maintain its dominance from 2022 to 2031, owing to presence of large patient population, strong presence of key players, ease of drug availability, well developed healthcare infrastructure, favorable reimbursement policies in healthcare system, higher number of research, development & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to increase in number of cancer affected population and rise in awareness related to different cancers.
The major companies profiled in the report include Amanta Healthcare Ltd., Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd, Fresenius Kabi AG, Grifols S.A., Henry Schein Inc., ICU Medical, Inc., JW Life Science, OtsUKa Pharmaceutical Co.,Ltd., Pfizer, Inc., Salius Pharma Private Limited , Sichuan Kelun Pharmaceutical Co. Ltd., Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intravenous solutions market analysis from 2021 to 2031 to identify the prevailing intravenous solutions market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the intravenous solutions market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global intravenous solutions market trends, key players, market segments, application areas, and market growth strategies.
Intravenous Solutions Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Composition |
|
 By End Users |
|
 By Region |
|
 Key Market Players | B. Braun Melsungen AG, Salius Pharma Private Limited, JW Life Science, Grifols S.A, Becton, Dickinson and Company, Axa Parenterals Ltd., Sichuan Kelun Pharmaceutical Co. Ltd, Eurolife Healthcare Pvt Ltd., Pfizer, Inc., Fresenius Kabi AG, Amanta Healthcare Ltd., Baxter International Inc., ICU Medical, Inc., Otsuka Pharmaceutical Co., Ltd., Soxa Formulations & Research (Pvt.) Ltd., Vifor Pharma Management Ltd., Henry Schein Inc. |
Analyst Review
The intravenous solutions therapy is a therapy that administers fluids, and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration and to provide nutrients for those who cannot consume food by mouth due to reduced mental state.
Europe accounted for the highest market share in 2021, due to availability of advance products, higher cancer prevalence, and heavy expenditure by the government on healthcare, followed by North America and Asia-Pacific. Asia Pacific is expected to exhibit fastest market growth due to increase in incidence of cancer. Pharmaceutical companies have focused on expanding their presence in emerging economies, which is anticipated to drive the market growth.
The total market value of intravenous solutions market calculated is $26,558.4 million in 2031.
The market value of intravenous solutions market in 2021 was $11,857.7 million.
The base year is 2021 in intravenous solutions market.
Asia-Pacific has the highest growth rate of 9.3% owing to increase in number of cancer affected population and rise in awareness related to different cancers.
The total parenteral nutrition segment is anticipated to grow with the largest share during the forecast period. This is attributed to the increase in the usage of total parenteral nutrition
Increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population are the key trends of intravenous solutions market.
Yes, the intravenous solutions market report provides PORTER Analysis
Yes, the intravenous solutions market companies are profiled in the report.
Loading Table Of Content...
